Oasmia issues new shares for acquiring an asset

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Oasmia issues new shares for acquiring an asset corresponding to SEK 25 million

Uppsala, Sweden, 2016-10-24 12:15 CEST (GLOBE NEWSWIRE) --  

As previously announced on October 24 2106 has Oasmia acquired a novel cancer project which was paid for by 3,080,000 newly issued shares at a share price of approximately SEK 8.12 per share 

In order to enable the transaction, the Board of Directors of Oasmia has, pursuant to the authorization granted by the annual general meeting held on September 26, 2016, resolved on a directed issue of 3,080,000 new shares. 

Through the issue, the number of shares in Oasmia increases by 3,080,000 from 115,959,310 to 119,039,310 and the share capital increases by SEK 308,000 from SEK 11,595,931 to SEK 11,903,931. The new issue results in an equity dilution of approximately 2.6 percent after the issue is completed. 

The information above has been made public in accordance with the Securities Market Act and the Financial Instruments Trading Act.  

Notes to editors: 

About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST). 

IMPORTANT INFORMATION Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ) securities in any jurisdiction, neither from Oasmia Pharmaceutical AB (publ) nor anyone else.

         Julian Aleksov          Tel: +46 18 50 54 40          E-mail: julian.aleksov@oasmia.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI and Storytelling Make Waves in Science Education

Updated Category News Views 4

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...

Continue Reading
HONA Faces Legal Heat: Investor Lawsuit Over Losses

Updated Category News Views 5

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

Continue Reading
Krispy Kreme Faces Legal Probe: Fiduciary Breach?

Updated Category News Views 3

Diving Deep into the Krispy Kreme Allegations Look, this isn't your run-of-the-mill donut drama. When you hear rumblings of corporate missteps, especially ones that involve potential breaches of fiduciary duties, it's time to perk up those ears. Over at Krispy Kreme, Inc. (NASDAQ:DNUT), there's some heat in the kitchen, and it's not just from frying those glazed beauties....

Continue Reading
CVS Health Under Fire: Fiduciary Duty Breach?

Updated Category News Views 2

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

Continue Reading
Quay Sunglasses: Luxury Looks, Affordable Prices

Updated Category News Views 3

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

Continue Reading
PACS Group Faces Legal Scrutiny: What to Watch

Updated Category News Views 3

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

Continue Reading
Jackson Wang's Fantasy IP Hits Hong Kong Stage

Updated Category News Views 4

A Star-Studded Fantasy Comes Alive Hong Kong isn't just about dim sum and skyline views—it's a magnet for celebrity showcases, and this time, Jackson Wang's pulling the strings. The guy's ventured beyond music and idol fame, diving head-first into creative visuals with his fantasy IP, "Under the Castle" (UTC). Pairing up with Ocean Park's Halloween Fest, he's cooked up...

Continue Reading
Geron Corp Faces Fiduciary Duty Investigation

Updated Category News Views 4

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

Continue Reading

Top 5 Most Recently Viewed Articles

Sarkee Capital Unveils Innovative G4 Trading System for Investors

Updated Category News Views 394

Revolutionizing Wealth Management with G4 5.0 Sarkee Capital, a visionary investment advisory firm based in London, has announced the global launch of its enhanced G4 Quantitative Trading System, now in version 5.0. This unique initiative marks a significant step in their mission to revolutionize wealth management for investors around the world. Pioneering Technology in...

Continue Reading
VantagePoint A.I. Named a Leading Tool for Financial Advisors

Updated Category News Views 144

VantagePoint A.I. Receives Recognition for Advanced Market Forecasting VantagePoint A.I., a frontrunner in artificial intelligence-based market forecasting, is thrilled to share its recent recognition by Kitces.com, a well-respected platform among financial professionals. With this acknowledgement, VantagePoint is poised to enhance its visibility across the financial...

Continue Reading
Damon Inc. Unveils Ambitious Plans for Electric Motorcycle Growth

Updated Category News Views 88

Damon Inc.'s Vision for Electric Motorcycles Damon Inc. (NASDAQ:DMN), a pioneer in the electric motorcycle sector, has revealed an ambitious roadmap aimed at transforming its vision into reality. With more than 3,000 refundable reservations in the pipeline, equating to potential revenue of $100 million, Damon is shifting focus from development towards the full-scale...

Continue Reading
Turnstone Biologics Faces Downgrade Amid Strategic Shift

Updated Category News Views 111

Turnstone Biologics Experiences a Significant Stock Downgrade Turnstone Biologics (NASDAQ: TSBX) recently faced a notable adjustment in its stock rating as BofA Securities decided to downgrade the company's stock from a Buy to Neutral. This shift in rating resulted in a drastic price target drop from $10.00 to just $0.50. Such changes come on the heels of the company...

Continue Reading
Critical Metals Corp Sees Surge Amid Geopolitical Shifts

Updated Category News Views 80

Explosive Growth for Critical Metals Corp Critical Metals Corp (NASDAQ: CRML) has recently experienced an impressive stock rally of 80%, capturing investors' attention amid speculation regarding geopolitical shifts that could influence rare earth acquisitions. This monumental growth reflects investors' increasing confidence in Critical Metals, as they position themselves...

Continue Reading